Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.
For information only — not medical advice. Always talk to your nephrologist.
17 FDA-approved therapies since 2018 — 8 in the last two years — plus 3 trials enrolling now.
New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.
Standard care is induction immunosuppression — steroids plus rituximab or cyclophosphamide — to bring the disease into remission. Your nephrologist and rheumatologist usually start here.
These are newer and recently approved therapies for ANCA-associated vasculitis / rapidly progressive GN — not the full standard of care. Ask your care team whether any fit your situation.
Oral C5a receptor antagonist
Evidence: Superior sustained remission at 52 weeks while sharply reducing glucocorticoid exposure.
Source: FDA prescribing information; ADVOCATE, NEJM 2021Verified 2026-07-18
Actively enrolling studies related to ANCA-associated vasculitis / rapidly progressive GN. Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.
No actively enrolling trials we're tracking for ANCA-associated vasculitis / rapidly progressive GN right now.
For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.
Jump straight to treatments and enrolling trials for a specific kidney diagnosis.
Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.
Get started free